Patents Examined by Anthony C. Caputa
  • Patent number: 7098003
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: August 29, 2006
    Assignee: Genentech, Inc.
    Inventors: Luc Desnoyers, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood
  • Patent number: 7071171
    Abstract: Novel genes expressed selectively by long-term dendritic cell (DC) lines (XS series) from murine epidermis which retain important features of resident epidermal Langerhans cells (LC) are provided. These genes encode distinct type II membrane-integrated polypeptides, each consisting of a cytoplasmic domain, a transmembrane domain, an extracellular connecting domain, and a C-terminal extracellular domain that exhibits significant homology to the carbohydrate recognition domains (CRD)) of C-type lectins. Expression of both genes is highly restricted to cells of DC lineage (including epidermal LC). Thus, these genes encode new, DC-specific members of the C-type lectin family, now termed “DC-associated C-type lectin-1 and -2” (dectin-1 and dectin-2). Two isoforms of the dectin-1 molecule and five isoforms of the dectin-2 molecule have also been identified. The invention further provides His-tagged fusion proteins comprising 6x histidine and the extracellular domain of dectin-1 or dectin-2.
    Type: Grant
    Filed: September 14, 1999
    Date of Patent: July 4, 2006
    Assignee: Board of Regents the University of Texas System
    Inventors: Kiyoshi Ariizumi, Akira Takashima
  • Patent number: 7041463
    Abstract: Methods for identifying modulators of receptor activity using orthologues of human receptors are described. Additionally, a method for identifying an animal model useful in the screening of potential therapeutic agents is provided. The genes for bradykinin B1 receptors from five mammalian species, vervet monkey, rhesus macaque, tree shrew, dog and pig, as well as the genes for CXCR2 receptors from chimpanzee, gorilla, orangutan, rhesus, vervet and baboon have been cloned and characterized and are described herein.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: May 9, 2006
    Assignee: Pharmacopeia Drug Discovery, Inc.
    Inventors: Robert Horlick, Jiuquao Zhao, Robert Swanson, Maria Webb, Barbara Strohl, John J. Baldwin, Douglas S. Auld, Xiao Ge Chen
  • Patent number: 7041646
    Abstract: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: May 9, 2006
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Clark Pan, James Whelan, Kevin B. Clairmont
  • Patent number: 7026454
    Abstract: The present invention involves a novel neuroendocrine growth factor or marker (“NEM”) identified in cultured prostate cancer cells and conjugates of NEM and a binding agent capable of inhibiting binding of NEM to its receptor.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: April 11, 2006
    Assignee: University of Kansas Medical Center
    Inventor: Girish V. Shah
  • Patent number: 7009043
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of Xenopus CENP-E (XCENP-E), antibodies to XCENP-E, methods of screening for CENP-E modulators using biologically active CENP-E, and kits for screening for CENP-E modulators.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: March 7, 2006
    Assignee: The Regents of the University of California
    Inventors: Kenneth W. Wood, Roman Sakowicz, Lawrence S. B. Goldstein, Don W. Cleveland
  • Patent number: 6942978
    Abstract: The present invention provides a TADG-12 protein and a DNA fragment encoding such protein. Also provided is a vector/host cell capable of expressing the DNA. The present invention further provides various methods of early detection of associated ovarian and other malignancies, and of interactive therapies for cancer treatment utilizing the DNA and/or protein disclosed herein.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: September 13, 2005
    Assignee: The Board of Trustees of the University of Arkansas
    Inventor: Timothy J. O'Brien
  • Patent number: 6872568
    Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: March 29, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen
  • Patent number: 6864066
    Abstract: Polynucleotide and polypeptide sequences encoding a novel tumor suppressor protein, EPLIN, are provided. Also included is a method for detecting a cell proliferative disorder associated with EPLIN. EPLIN is a marker that can be used diagnostically, prognostically and therapeutically over the course of cell proliferative disorders associated with EPLIN.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: March 8, 2005
    Assignee: The Regents of the University of California
    Inventors: David D. Chang, Raymond S. Maul
  • Patent number: 6828429
    Abstract: A nucleic acid sequence that exhibits prostate-specific expression and over-expression in tumor cells is disclosed. The sequence and fragments thereof are useful for detecting, diagnosing, preventing, and treating prostate cancer and other prostate related diseases. The sequence is also useful for measuring hormone responsiveness of prostate cancer cells.
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: December 7, 2004
    Assignee: Henry M. Jackson Foundation for the Advancement of Military Medicine
    Inventors: Shiv Srivastava, Vasantha Srikantan, Zhiqiang Zou, Judd W. Moul
  • Patent number: 6818746
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: November 16, 2004
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Luc Desnoyers, William I. Wood
  • Patent number: 6818405
    Abstract: The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR1 (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating diseases associated with a mineral ion imbalance in a human or an animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating an hydro-mineral imbalance in organs and tissues such as kidney, bone, dental enamel, dental ivory, gut matrix, pancreas or glandular gastric mucosa. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: November 16, 2004
    Assignee: Institut Pasteur
    Inventors: Catherine Rougeot, Francois Rougeon
  • Patent number: 6808930
    Abstract: An agent comprising a protein complex comprising an oligomeric form of &agr;-lactalbumin (MAL) and a further reagent which is combined with MAL such that it is carried into the nucleoplasm of cells which are susceptible to MAL. Agents of the type, where the further reagent is a therapeutic or labelling reagent, can be used in diagnosis and therapy in particular of cancer.
    Type: Grant
    Filed: August 30, 2000
    Date of Patent: October 26, 2004
    Inventors: Catharina Svanborg, Per Anders Hakansson
  • Patent number: 6797495
    Abstract: The present invention comprises a method for producing mammalian therapeutics free from prion contamination and cells for use in such methods. Such therapeutics are produced in somatic cells having a genome with an artificially altered PrP gene. The PrP gene in these cells may be ablated, or replaced by an exogenous inducible form of the PrP gene. The endogenous gene in the host cells may be disrupted, or disrupted and replaced by an exogenous PrP gene.
    Type: Grant
    Filed: April 9, 2001
    Date of Patent: September 28, 2004
    Assignee: The Regents of the University of California
    Inventor: Stanley B. Prusiner
  • Patent number: 6783986
    Abstract: Proteins having the activity of saccharose phosphate synthetase (SPS) and a process for obtaining the same.
    Type: Grant
    Filed: April 26, 1995
    Date of Patent: August 31, 2004
    Assignee: Aventis Crop Sciences GmbH
    Inventors: Charles Van Assche, Danielle Lando, Jean Michel Bruneau, Toni Alois Voelker, Monica Gervais
  • Patent number: 6770450
    Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers.
    Type: Grant
    Filed: July 20, 1999
    Date of Patent: August 3, 2004
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Neil H. Bander
  • Patent number: 6770457
    Abstract: The present invention relates to process of purifying the angiogensis inhibitor proteins expressed in E. coli and to the use of recombinant kringle 1-3 (; greenstatin) purified by the above process as a angiogenesis inhibitor and an anticancer agent. Particularly, according to the process of purifying the protein, the angiogenesis inhibitor proteins overexpressed are solubilized, refolded, and purified as a pure and active form. The greenstatin purified by the process specifically suppresses endothelial cell proliferation, anaiogenesis, and the growth of lung cancer, skin cancer, and brain tumor. Therefore, the process of this invention is applicable to the mass-production of angiogenesis inhibitor proteins such as greenstatin which is useful for the treatment of glaucoma, retinopathy, and cancers.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: August 3, 2004
    Assignee: Korea Green Cross Corporation
    Inventors: Weon Kyoo You, Seung Ho So, Byung Cheul Ahn, Hyosil Lee, Soo-Il Jung, Young jo Kim, Jong Hyuk Lee, Yong-Kil Hong, Young Ae Joe, Soo-Ik Chang
  • Patent number: 6770477
    Abstract: The present invention provides human Her-2/neu overexpression modulated proteins (HOMPS) and polynucleotides encoding HOMPS polypeptides. The invention also provides HOMPS containing expression vectors and host cells, HOMPS antibodies and methods of producing HOMPS. In addition, the invention provides methods for generating, identifying and manipulating HOMPS.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: August 3, 2004
    Assignee: The Regents of the University of California
    Inventors: Dennis J. Slamon, Juliana J. Oh
  • Patent number: 6767711
    Abstract: The present invention is directed to the use of antibodies or binding portions thereof or probes which recognize an antigen of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof. These antibodies or binding portions thereof or probes can be labeled and used for detection of such cells. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate cancer. Also disclosed is a hybridoma cell line which produces a monoclonal antibody recognizing antigens of normal, benign, hyperplastic, and cancerous prostate epithelial cells or portions thereof.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: July 27, 2004
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Neil H. Bander
  • Patent number: 6767541
    Abstract: The present invention provides methods for obtaining genetic profiles of cancer cells in order to assess the status of a cancer in an individual. In addition, the present invention provides methods for inhibiting the growth of cancer cells that exhibit certain genetic profiles. These methods identify an important link between HER-2/neu overexpression and loss of growth inhibition by the TGF-&bgr; signaling pathway in cancer cells. Compositions as well as therapeutic and diagnostic methodologies based on this disclosure are provided.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: July 27, 2004
    Assignees: The Regents of the University of California, Amgen Inc.
    Inventors: Dennis J. Slamon, Cindy A. Wilson, Frank J. Calzone